Patent number: 11897872
Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.
Type:
Grant
Filed:
October 31, 2022
Date of Patent:
February 13, 2024
Assignee:
Janssen Pharmaceutica NV
Inventors:
Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro
Publication number: 20230227438
Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.
Type:
Application
Filed:
October 31, 2022
Publication date:
July 20, 2023
Inventors:
Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro
Patent number: 11505546
Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.
Type:
Grant
Filed:
March 25, 2021
Date of Patent:
November 22, 2022
Assignee:
Janssen Pharmaceutica NV
Inventors:
Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro
Publication number: 20220081428
Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.
Type:
Application
Filed:
March 25, 2021
Publication date:
March 17, 2022
Inventors:
Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro